Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxLYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer
/0 Comments/in Preclinical Research, PROTACs/by MaxPhase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxAI Platform Aims to Revolutionize Cancer Immunotherapy
/0 Comments/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxA new AI platform developed by researchers at the Technical University of Denmark and the Scripps Research Institute has dramatically accelerated the design of specialized protein molecules called “minibinders” to enhance cancer immunotherapy. Normally, T cells recognize cancer cells by detecting protein fragments (peptides) presented on their surface by molecules known as pMHCs, but harnessing […]
FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial For BL-M14D1 For Neuroendocrine Cancers
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 30/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Made it again this week! A small collection of interesting studies, as we wait for ESMO 2025 this coming fall. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the […]
New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets
/0 Comments/in Immunotherapy, Preclinical Research/by MaxScientists Trace Deadly Shift in Prostate Cancer to Two Key Genes
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025
- Phase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors August 29, 2025